KRRO

Rating neutralTentativeAI Memo

Korro Bio

As of 2026-10-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Novo Nordisk collaboration hold-period outcome • 2026-11-11

Base target: $10 / p=50% prob

Biggest risk

Trial clearance or enrollment may slip, and preclinical KRRO-111 results may not translate to patients. Korro's earlier KRRO-110 AATD trial did not reach projected protein levels; the Novo Nordisk collaboration remains paused under the June-quarter filing [#SEC-10Q-2026-08-06].

Invalidation

Break below $4 or thesis failure.

What would change my mind?

KRRO-121 trial clearance and dosing, followed by credible human data, could validate Korro's platform; a third candidate and the reported runway provide additional development capacity [#8-K-2026-08-19][#SEC-8K-2026-08-06].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-02

Base target

$10

p=50%

Bull target

$18

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

KRRO-111 clinical translation and runway
KRRO-121 trial clearance and dosing, followed by credible human data, could validate Korro's platform; a third candidate and the reported runway provide additional development capacity [#8-K-2026-08-19][#SEC-8K-2026-08-06].
At the $9.71 October 1 anchor, the supplied market capitalization is about $143 million versus $137.9 million of June 30 cash, equivalents and marketable securities; this is a gross-cash comparison, not net cash or liquidation value.

BearKey bullets

Cash runway is a management projection; sustained R&D spending, financing needs and dilution remain risks [#SEC-8K-2026-08-06].
First-in-human KRRO-121 regulatory, safety, enrollment and dosing risks [#8-K-2026-08-19].
KRRO-110's terminated trial missed projected patient protein levels; GalNAc-conjugated KRRO-111 efficacy remains unproven in humans [#SEC-10Q-2026-08-06].

WatchKey bullets

Novo Nordisk collaboration hold-period outcome

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $10 (p=50%)

Target spread vs base: +80% / -60%

Scenario probabilities

Bull Target: $18 (p=25%)Base Target: $10 (p=50%)Bear Target: $4 (p=25%)

Commentary

The structured prior is positive and identifies several program milestones, but low coverage and binary clinical risk favor monitoring. WVE is a close AATD program comparator and PRQR a platform comparator; neither supplies a like-for-like valuation benchmark. The packet supplies no usable recent-news, social, options, short-interest, employee-rating or analyst-revision series; zero fields mean unavailable, not measured neutrality. The $9.71 October 1 anchor alone does not establish a cause for the recent price level.

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

KRRO-111 clinical translation and runway

Scenarios

Bull Target (Scenario probability)

$18 / p=25% prob

Base Target (Scenario probability)

$10 / p=50% prob

Bear Target (Scenario probability)

$4 / p=25% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-11
Novo Nordisk collaboration hold-period outcome
The November 2025 amendment paused research activities and related obligations for 12 months. The hold-period anniversary creates a monitoring point, not a commitment to resume work; the June quarter had no collaboration revenue [#SEC-10Q-2026-08-06].
Prob 40.00% • Move 12.00% • Priced-in 20.00%
EVENT2026-12-31
KRRO-121 trial clearance and first dosing
Korro submitted its proposed first-in-human Phase 1/2 trial to an Australian ethics committee on August 19. Clearance, enrollment and dosing have not been confirmed; management targeted a second-half 2026 start. The study would test safety, pharmacokinetics and effects in healthy volunteers and participants with urea cycle disorders [#8-K-2026-08-19][#SEC-8K-2026-08-06].
Prob 60.00% • Move 25.00% • Priced-in 40.00%
EVENT2026-12-31
Third GalNAc candidate nomination
Management targeted nomination of a third GalNAc-conjugated development candidate in the second half of 2026. Nomination would broaden the pipeline but would not establish clinical efficacy [#SEC-8K-2026-08-06].
Prob 60.00% • Move 10.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

KRRO-111 clinical translation and runway
2028-12-31
KRRO-111's reported AATD editing results are from a mouse model, not patients. Korro reported $137.9 million in cash, equivalents and marketable securities at June 30 and projected runway into the second half of 2028. The date is an assessment horizon, not an announced KRRO-111 readout date [#SEC-8K-2026-08-06].
Prob 45% • Move 45% • Priced-in 20%

Risks

Cash runway is a management projection; sustained R&D spending, financing needs and dilution remain risks [#SEC-8K-2026-08-06].
First-in-human KRRO-121 regulatory, safety, enrollment and dosing risks [#8-K-2026-08-19].
KRRO-110's terminated trial missed projected patient protein levels; GalNAc-conjugated KRRO-111 efficacy remains unproven in humans [#SEC-10Q-2026-08-06].
The Novo Nordisk research collaboration was paused for 12 months from November 2025; resumption and future economics are uncertain [#SEC-10Q-2026-08-06].

Peers

Symbol	Summary
WVE	Direct AATD and delivery-modality comparator: Wave's WVE-006 and Korro's KRRO-111 are subcutaneously delivered, GalNAc-conjugated RNA-editing oligonucleotides. Wave reported patient data from its RestorAATion-2 trial in May 2026, whereas KRRO-111's cited results remain in mice. This is a useful clinical-translation and competitive benchmark, not a transferable valuation multiple. Company source: https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-positive-update-restoraation-2
PRQR	Direct RNA-editing-platform comparator, but not an AATD indication peer: ProQR's GalNAc-conjugated AX-0810 uses RNA editing to modulate a liver target for cholestatic disease. ProQR reported Phase 1 target-engagement data in healthy volunteers in June 2026; KRRO-121 has not yet confirmed first dosing. The different targets and clinical stages limit valuation comparisons. Company source: https://www.proqr.com/press-releases/proqr-announces-positive-phase-1-target-engagement-data-for-ax-0810-establishing-first-clinical-validation-of-the-axiomer-rna-editing-platform

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…

Symbol

Summary

WVE

Direct AATD and delivery-modality comparator: Wave's WVE-006 and Korro's KRRO-111 are subcutaneously delivered, GalNAc-conjugated RNA-editing oligonucleotides. Wave reported patient data from its RestorAATion-2 trial in May 2026, whereas KRRO-111's cited results remain in mice. This is a useful clinical-translation and competitive benchmark, not a transferable valuation multiple. Company source: https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-positive-update-restoraation-2

PRQR

Direct RNA-editing-platform comparator, but not an AATD indication peer: ProQR's GalNAc-conjugated AX-0810 uses RNA editing to modulate a liver target for cholestatic disease. ProQR reported Phase 1 target-engagement data in healthy volunteers in June 2026; KRRO-121 has not yet confirmed first dosing. The different targets and clinical stages limit valuation comparisons. Company source: https://www.proqr.com/press-releases/proqr-announces-positive-phase-1-target-engagement-data-for-ax-0810-establishing-first-clinical-validation-of-the-axiomer-rna-editing-platform